Business Description
SenzaGen AB
ISIN : SE0010219626
Total Employee Number:
33Compare
Compare
Traded in other countries / regions
SENZA.Sweden26S.Germany IPO Date
2026-03-31Description
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.14 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -1.52 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.99 | |||||
Beneish M-Score | -2.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year EBITDA Growth Rate | 24 | |||||
3-Year EPS without NRI Growth Rate | 21.1 | |||||
3-Year FCF Growth Rate | 18.7 | |||||
3-Year Book Growth Rate | -10.8 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.78 | |||||
9-Day RSI | 38.53 | |||||
14-Day RSI | 42.24 | |||||
3-1 Month Momentum % | -4.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.95 | |||||
Quick Ratio | 2.8 | |||||
Cash Ratio | 1.73 | |||||
Days Inventory | 55.09 | |||||
Days Sales Outstanding | 70.19 | |||||
Days Payable | 77.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | -14.89 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.42 | |||||
Operating Margin % | -17.98 | |||||
Net Margin % | -23.22 | |||||
EBITDA Margin % | -19.77 | |||||
FCF Margin % | -25.31 | |||||
OCF Margin % | -16.24 | |||||
ROE % | -17.17 | |||||
ROA % | -12.58 | |||||
ROIC % | -14.42 | |||||
3-Year ROIIC % | -324.18 | |||||
ROC (Joel Greenblatt) % | -105.71 | |||||
ROCE % | -12.45 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.72 | |||||
PB Ratio | 1.91 | |||||
Price-to-Tangible-Book | 3.93 | |||||
EV-to-EBIT | -12.97 | |||||
EV-to-EBITDA | -12.97 | |||||
EV-to-Revenue | 2.57 | |||||
EV-to-FCF | -10.21 | |||||
Price-to-GF-Value | 0.83 | |||||
| Price-to-Net-Current-Asset-Value | 5.9 | |||||
| Price-to-Net-Cash | 47.2 | |||||
Earnings Yield (Greenblatt) % | -7.72 | |||||
FCF Yield % | -8.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SenzaGen AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.432 | ||
| EPS (TTM) (€) | -0.042 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 42.24 | ||
| 14-Day ATR (€) | 0.007156 | ||
| 20-Day SMA (€) | 0.4908 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.45 - 0.55 | ||
| Shares Outstanding (Mil) | 32.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SenzaGen AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SenzaGen AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 103 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 103 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 26 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 26 days | ||
| General meeting for 2026 | 2026-05-12 14:00 | 0.51 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 09:00 | 0.51 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.51 (+0.00%) | ||
| Annual report for 2025 | 2026-04-21 | 0.55 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-13 09:00 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-02-13 | -- |
Show
Entries
SenzaGen AB Frequently Asked Questions
What is SenzaGen AB(FRA:26S)'s stock price today?
The current price of FRA:26S is €0.47. The 52 week high of FRA:26S is €0.55 and 52 week low is €0.45.
When is next earnings date of SenzaGen AB(FRA:26S)?
The next earnings date of SenzaGen AB(FRA:26S) is 2026-08-20.
Does SenzaGen AB(FRA:26S) pay dividends? If so, how much?
SenzaGen AB(FRA:26S) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SenzaGen's Final Validation Report for the Animal-free Allergy Test GARDpotencyâ„¢ has Been Submitted to the Regulatory Authorities | 2018-07-09 |
Articles on SenzaGen AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers